Baohua Qian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Baohua Qian has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Yan Zang
Department of Blood Transfusion The First Affiliated Hospital of Naval Medical University Shanghai China
8 shared publicationsHaihui Gu
Department of Transfusion, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China
5 shared publicationsHuijun Guo
Department of Transfusion, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China
3 shared publicationsXiaohua Tu
Department of Transfusion, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China
3 shared publicationsZhanshan Cha
Department of Transfusion, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China
3 shared publications- Anmei Deng
Department of Laboratory Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 22 April 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (3) , 372-380
Exploration of the association between 91 inflammatory proteins and immune thrombocytopenia: a two-sample Mendelian randomization analysis
Objective: This study aimed to explore the association between 91 circulating inflammatory proteins and immune thrombocytopenia (ITP) using Mendelian randomization (MR). Methods: Data from genome-wide association studies (GWAS) on 91 inflammatory proteins were aggregated from the Olink Target platform, involving 14,824 participants. ITP data were sourced from the Integrative Epidemiology Unit OPEN GWAS project, which included 675 ITP patients and 488,749 controls. Mendelian randomization analysis was primarily conducted using inverse-variance weighting (IVW), supplemented by MR-Egger, weighted median, simple mode, and weighted mode. Pleiotropy and heterogeneity of the instrumental variables were assessed using the MR-Egger-intercept test and Cochran’s Q test, with results visualized through scatter plots, funnel plots, and leave-one-out plots. Results: The IVW method indicated an association between six specific circulating inflammatory proteins and ITP. Four proteins (CCL4, CXCL9, IL-12B, and SCF) were positively associated with ITP, while two proteins (IL-1α, TRANCE) showed a negative correlation. Conclusion: The findings suggest a potential link between circulating inflammatory proteins and ITP, providing insights for future therapeutic strategies and biomarker identification.
- 22 April 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (3) , 372-380
Open AccessExploration of the association between 91 inflammatory proteins and immune thrombocytopenia: a two-sample Mendelian randomization analysis
Objective: This study aimed to explore the association between 91 circulating inflammatory proteins and immune thrombocytopenia (ITP) using Mendelian randomization (MR). Methods: Data from genome-wide association studies (GWAS) on 91 inflammatory proteins were aggregated from the Olink Target platform, involving 14,824 participants. ITP data were sourced from the Integrative Epidemiology Unit OPEN GWAS project, which included 675 ITP patients and 488,749 controls. Mendelian randomization analysis was primarily conducted using inverse-variance weighting (IVW), supplemented by MR-Egger, weighted median, simple mode, and weighted mode. Pleiotropy and heterogeneity of the instrumental variables were assessed using the MR-Egger-intercept test and Cochran’s Q test, with results visualized through scatter plots, funnel plots, and leave-one-out plots. Results: The IVW method indicated an association between six specific circulating inflammatory proteins and ITP. Four proteins (CCL4, CXCL9, IL-12B, and SCF) were positively associated with ITP, while two proteins (IL-1α, TRANCE) showed a negative correlation. Conclusion: The findings suggest a potential link between circulating inflammatory proteins and ITP, providing insights for future therapeutic strategies and biomarker identification.
- Open Access
- 3 October 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-10
Evaluation of prothrombotic risk of two PROC hotspot mutations (Arg189Trp and Lys193del) in Chinese population: a retrospective study
Background: R189W and K193del of protein C (PC) were hotspot mutations in Chinese population with venous thromboembolism (VTE), but almost two-thirds of patients with above mutations coexisting with other genetically or aquiredly prothrombotic risk factors. The aim of this study is to clarify the independent contributions of R189W or K193del to VTE risk. Methods: 490 unrelated patients with a personal history of VTE and 410 healthy participants were enrolled in this study. Data of their demographics, family history, genetic and acquired thrombosis risk factors were collected and statistically analyzed. Results: PC R189W and K193del were identified in 3/410 (0.7%) and 7/410 (1.7%) healthy controls, and in 27/490 (5.5%) and 43/490 (8.8%) patients with VTE, respectively. Notably, about 70% of these mutant carriers combined with other genetic or acquired thrombophilic factors. After adjustment for age, gender, other inherited and acquired risk factors, we demonstrated that R189W and K193del were associated with 5.781-fold and 4.365-fold increased risk of VTE, respectively, which were significantly lower than the prothrombotic risk of anticoagulant deficiencies induced from rare mutations. Independent R189W or K193del mutation was not associated with earlier first-onset age as well as higher recurrent rate of VTE. However, combination of other genetic or acquired thrombophilic factors had supra-additive effects on those consequences. The more additional risk factors the patients had, the younger first-onset ages and higher risk of recurrence would be. Conclusions: As the most frequent mutations for PC deficiency in Chinese population, both R189W and K193del mutations had limited independent contributions to VTE development compared with other rare mutations in PROC gene, but may act in concert with other genetic defects or acquired thrombotic risk factors to produce the final severe phenotype.
- 3 October 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-10
Open AccessEvaluation of prothrombotic risk of two PROC hotspot mutations (Arg189Trp and Lys193del) in Chinese population: a retrospective study
Background: R189W and K193del of protein C (PC) were hotspot mutations in Chinese population with venous thromboembolism (VTE), but almost two-thirds of patients with above mutations coexisting with other genetically or aquiredly prothrombotic risk factors. The aim of this study is to clarify the independent contributions of R189W or K193del to VTE risk. Methods: 490 unrelated patients with a personal history of VTE and 410 healthy participants were enrolled in this study. Data of their demographics, family history, genetic and acquired thrombosis risk factors were collected and statistically analyzed. Results: PC R189W and K193del were identified in 3/410 (0.7%) and 7/410 (1.7%) healthy controls, and in 27/490 (5.5%) and 43/490 (8.8%) patients with VTE, respectively. Notably, about 70% of these mutant carriers combined with other genetic or acquired thrombophilic factors. After adjustment for age, gender, other inherited and acquired risk factors, we demonstrated that R189W and K193del were associated with 5.781-fold and 4.365-fold increased risk of VTE, respectively, which were significantly lower than the prothrombotic risk of anticoagulant deficiencies induced from rare mutations. Independent R189W or K193del mutation was not associated with earlier first-onset age as well as higher recurrent rate of VTE. However, combination of other genetic or acquired thrombophilic factors had supra-additive effects on those consequences. The more additional risk factors the patients had, the younger first-onset ages and higher risk of recurrence would be. Conclusions: As the most frequent mutations for PC deficiency in Chinese population, both R189W and K193del mutations had limited independent contributions to VTE development compared with other rare mutations in PROC gene, but may act in concert with other genetic defects or acquired thrombotic risk factors to produce the final severe phenotype.
- 6 September 2023
- Published by Wiley in Vox Sanguinis
- Vol. 118 (11) , 955-965
Evaluation of a rail logistics transmission system for the transportation of blood components within a medical centre
Background and Objectives: Rail logistics transmission systems (RLTSs) are commonly used for the transportation of blood samples, pathological specimens and other medical materials in many hospitals, as they are rapid, secure, costeffective and intelligent. However, few studies have evaluated blood component transportation from blood banks to the patient care areas of hospitals using RLTS. In this study, we evaluate the RLTS used for the transportation of blood components within a medical centre. Materials and Methods: The dispatch of blood components, including packed red blood cells (pRBCs), fresh frozen plasma (FFP), cryoprecipitate and platelet units, from a blood bank to critical care areas or general wards was done using RLTS. Parameters such as the delivery time, temperature, physical integrity and blood component quality were evaluated via analytical testing using specimens obtained before and after transportation by RLTS. Results: The turnaround time and temperature of all tested blood units via RLTS transportation were able to meet the clinical demands of blood component delivery ( median time: 323 s [ 118-668 s]; temperature variation: 4.5-8.9 degrees C for pRBCs and FFP and 21.5-23.5 degrees C for cryoprecipitate and platelet units). Furthermore, parameters of pRBC quality, including the haemolysis index and potassium and lactate dehydrogenase levels in plasma, were not significantly different before and after transportation through RLTS. Similarly, RLTS transportation affected neither the basic coagulation test results in FFP and cryoprecipitate specimens nor platelet aggregation and activation markers in apheresis platelet specimens. Conclusion: Hospital-wide delivery of blood components via RLTS seems to be safe, reliable and cost-effective and does not have any negative impact on blood quality. Therefore, the establishment of standard criteria, protocols and guidelines based on further studies is needed.
- 6 September 2023
- Published by Wiley in Vox Sanguinis
- Vol. 118 (11) , 955-965
Evaluation of a rail logistics transmission system for the transportation of blood components within a medical centre
Background and Objectives: Rail logistics transmission systems (RLTSs) are commonly used for the transportation of blood samples, pathological specimens and other medical materials in many hospitals, as they are rapid, secure, costeffective and intelligent. However, few studies have evaluated blood component transportation from blood banks to the patient care areas of hospitals using RLTS. In this study, we evaluate the RLTS used for the transportation of blood components within a medical centre. Materials and Methods: The dispatch of blood components, including packed red blood cells (pRBCs), fresh frozen plasma (FFP), cryoprecipitate and platelet units, from a blood bank to critical care areas or general wards was done using RLTS. Parameters such as the delivery time, temperature, physical integrity and blood component quality were evaluated via analytical testing using specimens obtained before and after transportation by RLTS. Results: The turnaround time and temperature of all tested blood units via RLTS transportation were able to meet the clinical demands of blood component delivery ( median time: 323 s [ 118-668 s]; temperature variation: 4.5-8.9 degrees C for pRBCs and FFP and 21.5-23.5 degrees C for cryoprecipitate and platelet units). Furthermore, parameters of pRBC quality, including the haemolysis index and potassium and lactate dehydrogenase levels in plasma, were not significantly different before and after transportation through RLTS. Similarly, RLTS transportation affected neither the basic coagulation test results in FFP and cryoprecipitate specimens nor platelet aggregation and activation markers in apheresis platelet specimens. Conclusion: Hospital-wide delivery of blood components via RLTS seems to be safe, reliable and cost-effective and does not have any negative impact on blood quality. Therefore, the establishment of standard criteria, protocols and guidelines based on further studies is needed.
- 5 July 2021
- Published by Taylor & Francis in Platelets
- Vol. 33 (3) , 462-470
The plant hormone abscisic acid stimulates megakaryocyte differentiation from human iPSCs in vitro
In the clinic, the supply of platelets is frequently insufficient to meet transfusion needs. To address this issue, many scientists have established the derivation of functional platelets from CD34+ cells or human pluripotent stem cells (PSCs). However, the yield of platelets is still far below what is required. Here we found that the plant hormone abscisic acid (ABA) could increase the generation of megakaryocytes (MKs) and platelets from human induced PSCs (hiPSCs). During platelet derivation, ABA treatment promoted the generation of CD34+/CD45+ HPCs and CD41+ MKs on day 14 and then increased CD41+/CD42b+ MKs and platelets on day 19. Moreover, we found ABA-mediated activation of Akt and ERK1/2 signal pathway through receptors LANCL2 and GRP78 in a PKA-dependent manner on CD34+/CD45+ cells. In conclusion, our data suggest that ABA treatment can promote CD34+/CD45+ HPC proliferation and CD41+ MK differentiation.
- 5 July 2021
- Published by Taylor & Francis in Platelets
- Vol. 33 (3) , 462-470
The plant hormone abscisic acid stimulates megakaryocyte differentiation from human iPSCs in vitro
In the clinic, the supply of platelets is frequently insufficient to meet transfusion needs. To address this issue, many scientists have established the derivation of functional platelets from CD34+ cells or human pluripotent stem cells (PSCs). However, the yield of platelets is still far below what is required. Here we found that the plant hormone abscisic acid (ABA) could increase the generation of megakaryocytes (MKs) and platelets from human induced PSCs (hiPSCs). During platelet derivation, ABA treatment promoted the generation of CD34+/CD45+ HPCs and CD41+ MKs on day 14 and then increased CD41+/CD42b+ MKs and platelets on day 19. Moreover, we found ABA-mediated activation of Akt and ERK1/2 signal pathway through receptors LANCL2 and GRP78 in a PKA-dependent manner on CD34+/CD45+ cells. In conclusion, our data suggest that ABA treatment can promote CD34+/CD45+ HPC proliferation and CD41+ MK differentiation.
- Retraction
- 6 June 2016
- Published by Springer Nature in Molecular Biology Reports
- Vol. 43 (7) , 753
Retraction Note to: Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma
- 6 June 2016
- Published by Springer Nature in Molecular Biology Reports
- Vol. 43 (7) , 753
RetractionRetraction Note to: Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma
- 26 February 2015
- Published by Springer Nature in Journal of Anesthesia
- Vol. 29 (4) , 570-579
Effects of volatile vs. propofol-based intravenous anesthetics on the alveolar inflammatory responses to one-lung ventilation: a meta-analysis of randomized controlled trials
The aim of this meta-analysis is to compare the potential effects of inhalation anesthetics with total intravenous anesthetics on alveolar cytokine expression and lung-related clinical outcomes in patients undergoing one-lung ventilation (OLV) for thoracic surgery. We retrieved the PubMed, EMBASE, and the Cochrane Library respectively to identify randomized controlled trials comparing different anesthetics (volatile anesthetics vs. intravenous anesthetics) on the pulmonary inflammatory response to OLV. The primary outcomes were the levels of alveolar concentrations of inflammatory cytokines. Eight randomized controlled trials that included 365 patients were screened. Overall, there were significant differences in the concentration of alveolar inflammatory mediators between volatile group and intravenous group, in which volatile group had lower levels of TNF-α (SMD −1.51; 95 % CI −2.15 to −0.87; p < 0.001), IL-6 (SMD −0.70; 95 % CI −0.99 to −0.41; p < 0.001) and IL-8 (SMD −1.32; 95 % CI −2.20 to −0.45; p = 0.003). The overall number of pulmonary complications in the volatile group was smaller (RR 0.42; 95 % CI 0.23–0.77; p = 0.005) and patients in that group had significantly abridged hospitalization stay (WMD −3.59 days; 95 % CI −5.70 to −1.48 days; p = 0.001). Inhalation anesthetics might be preferable in patients undergoing OLV for thoracic surgery and their protective effects might work via attenuating inflammatory responses.
- 26 February 2015
- Published by Springer Nature in Journal of Anesthesia
- Vol. 29 (4) , 570-579
Effects of volatile vs. propofol-based intravenous anesthetics on the alveolar inflammatory responses to one-lung ventilation: a meta-analysis of randomized controlled trials
The aim of this meta-analysis is to compare the potential effects of inhalation anesthetics with total intravenous anesthetics on alveolar cytokine expression and lung-related clinical outcomes in patients undergoing one-lung ventilation (OLV) for thoracic surgery. We retrieved the PubMed, EMBASE, and the Cochrane Library respectively to identify randomized controlled trials comparing different anesthetics (volatile anesthetics vs. intravenous anesthetics) on the pulmonary inflammatory response to OLV. The primary outcomes were the levels of alveolar concentrations of inflammatory cytokines. Eight randomized controlled trials that included 365 patients were screened. Overall, there were significant differences in the concentration of alveolar inflammatory mediators between volatile group and intravenous group, in which volatile group had lower levels of TNF-α (SMD −1.51; 95 % CI −2.15 to −0.87; p < 0.001), IL-6 (SMD −0.70; 95 % CI −0.99 to −0.41; p < 0.001) and IL-8 (SMD −1.32; 95 % CI −2.20 to −0.45; p = 0.003). The overall number of pulmonary complications in the volatile group was smaller (RR 0.42; 95 % CI 0.23–0.77; p = 0.005) and patients in that group had significantly abridged hospitalization stay (WMD −3.59 days; 95 % CI −5.70 to −1.48 days; p = 0.001). Inhalation anesthetics might be preferable in patients undergoing OLV for thoracic surgery and their protective effects might work via attenuating inflammatory responses.
- Open Access
- 6 February 2015
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 8 (1) , 8
Hematology research output from Chinese authors and other countries: a 10-year survey of the literature
Hematologic disease affects people of all ages worldwide. In the past decade, researchers have made great progress in the field of hematology. In the present study we compared the hematology research output from China and other countries (USA, Germany, UK, Japan and South Korea) over the past 10 years and 5 years. The related articles were extracted based on the PubMed database. We recorded the number of publications, clinical trials, randomized controlled trials, meta-analyses, case reports, reviews, citations, impact factors, articles in the top 10 journals and most published journals to assess the quantity and quality of research output in each region. A total of 120,641 hematology-related articles were published from 2004 to 2013. The USA accounted for 27.13% (32,732/120,641) of the publications, followed by Germany (7,479/120,641; 6.20%), Japan (6,347/120,641; 5.26%), the UK (5,453/120,641; 4.52%), China (2,924/120,641; 2.42%) and South Korea (1,413/120,641; 1.17%). The ranking for cumulative impact factors was as follows: USA; Germany; UK; Japan; China and South Korea. The median impact factors in the UK, USA, and Germany were higher than Japan, South Korea, and China. Interestingly, the median impact factors in the three Asia countries were similar both in 2004–2013 and 2009–2013. The UK had the highest percentage of publications in the top 25% of journals, while China lagged behind and ranked last. When comparing the number of articles in the top 10 journals, the results were similar to the IF findings. Germany had the highest number of average citations, while China had the lowest number of average citation. The status of hematology research output from the 6 countries in 2009–2013 had little difference from 2004–2013. Thus, the USA has had a dominant role in hematologic research in the past 10 years. Overall, the quality of publications in European countries was better than Asia countries. Although China has made considerable progress in hematology research, the quality of research needs improvement.
- 6 February 2015
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 8 (1) , 8
Open AccessHematology research output from Chinese authors and other countries: a 10-year survey of the literature
Hematologic disease affects people of all ages worldwide. In the past decade, researchers have made great progress in the field of hematology. In the present study we compared the hematology research output from China and other countries (USA, Germany, UK, Japan and South Korea) over the past 10 years and 5 years. The related articles were extracted based on the PubMed database. We recorded the number of publications, clinical trials, randomized controlled trials, meta-analyses, case reports, reviews, citations, impact factors, articles in the top 10 journals and most published journals to assess the quantity and quality of research output in each region. A total of 120,641 hematology-related articles were published from 2004 to 2013. The USA accounted for 27.13% (32,732/120,641) of the publications, followed by Germany (7,479/120,641; 6.20%), Japan (6,347/120,641; 5.26%), the UK (5,453/120,641; 4.52%), China (2,924/120,641; 2.42%) and South Korea (1,413/120,641; 1.17%). The ranking for cumulative impact factors was as follows: USA; Germany; UK; Japan; China and South Korea. The median impact factors in the UK, USA, and Germany were higher than Japan, South Korea, and China. Interestingly, the median impact factors in the three Asia countries were similar both in 2004–2013 and 2009–2013. The UK had the highest percentage of publications in the top 25% of journals, while China lagged behind and ranked last. When comparing the number of articles in the top 10 journals, the results were similar to the IF findings. Germany had the highest number of average citations, while China had the lowest number of average citation. The status of hematology research output from the 6 countries in 2009–2013 had little difference from 2004–2013. Thus, the USA has had a dominant role in hematologic research in the past 10 years. Overall, the quality of publications in European countries was better than Asia countries. Although China has made considerable progress in hematology research, the quality of research needs improvement.
- Open Access
- 26 January 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (1) , e0117704
The Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with an unclear etiology. This study aims to investigate the role of IL-23/Th17 pathway in patients with ITP. The gene expressions of IL-17, IL-23 and their receptors in ITP patients and healthy controls were analyzed by quantitative real-time PCR. ELISA was used to test the IL-17 and IL-23 levels in plasma. Flow cytometry was used to detect the frequency of Th17 cells. The correlation between plasma IL-23 and IL-17 levels, Th17 cells, platelets were analyzed. The level of Th17-related cytokines was measured by ELISA following stimulation with IL-23. Subsequently, the IL-23 and IL-17 levels were measured in patients post-treatment. The PBMCs of ITP patients showed increased mRNA expression levels in each of the following: IL-23p19, IL-12p40, IL-23R, IL-12Rβ1, IL-17A, IL-17F, and RORC. In addition, elevated Th17 cells and plasma IL-17, IL-23 levels were also observed in these ITP patients. Furthermore, it was found that IL-23 levels in plasma are positively correlated with IL-17 levels and Th17 cells, yet negatively correlated with platelet count. Following IL-23 stimulation in vitro, IL-17 levels showed significant elevation. Furthermore, both IL-23 and IL-17 levels decreased after effective treatment. The IL-23/Th17 pathway may be involved in the pathogenesis of ITP through enhancement of the Th17 response. Moreover, our results suggest that the IL-23/Th17 pathway is a potential therapeutic target in future attempts of ITP treatment.
- 26 January 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (1) , e0117704
Open AccessThe Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with an unclear etiology. This study aims to investigate the role of IL-23/Th17 pathway in patients with ITP. The gene expressions of IL-17, IL-23 and their receptors in ITP patients and healthy controls were analyzed by quantitative real-time PCR. ELISA was used to test the IL-17 and IL-23 levels in plasma. Flow cytometry was used to detect the frequency of Th17 cells. The correlation between plasma IL-23 and IL-17 levels, Th17 cells, platelets were analyzed. The level of Th17-related cytokines was measured by ELISA following stimulation with IL-23. Subsequently, the IL-23 and IL-17 levels were measured in patients post-treatment. The PBMCs of ITP patients showed increased mRNA expression levels in each of the following: IL-23p19, IL-12p40, IL-23R, IL-12Rβ1, IL-17A, IL-17F, and RORC. In addition, elevated Th17 cells and plasma IL-17, IL-23 levels were also observed in these ITP patients. Furthermore, it was found that IL-23 levels in plasma are positively correlated with IL-17 levels and Th17 cells, yet negatively correlated with platelet count. Following IL-23 stimulation in vitro, IL-17 levels showed significant elevation. Furthermore, both IL-23 and IL-17 levels decreased after effective treatment. The IL-23/Th17 pathway may be involved in the pathogenesis of ITP through enhancement of the Th17 response. Moreover, our results suggest that the IL-23/Th17 pathway is a potential therapeutic target in future attempts of ITP treatment.
- Open Access
- 21 November 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e110472
MicroRNA-383 Regulates the Apoptosis of Tumor Cells through Targeting Gadd45g
MicroRNAs (miRNAs) are a class of small non-coding single-stranded RNA molecules that inhibit gene expression at post-transcriptional level. Gadd45g (growth arrest and DNA-damage-inducible 45 gamma) is a stress-response protein, which has been implicated in several biological processes, including DNA repair, the cell cycle and cell differentiation. In this work, we found that miR-383 is a negative regulator of Gadd45g. Forced expression of miR-383 decreased the expression of Gadd45g through binding to the 3′ untranslated region (3′-UTR), whereas inhibition of miR-383 increased Gadd45g expression. The presence of miR-383 increased the cellular sensitivity to DNA damage in breast cancer cells, which was rescued by ectopic expression of Gadd45g without the 3′-UTR. miR-383 also regulates the expression of Gadd45g in embryonic stem (ES) cells, but not their apoptosis under genotoxic stress. miR-383 was further showed to negatively regulate ES cell differentiation via targeting Gadd45g, which subsequently modulates the pluripotency-associated genes. Taken together, our study demonstrates that miR-383 is a negative regulator of Gadd45g in both tumor cells and ES cells, however, has distinct function in regulating cell apoptosis. miR-383 may be used as antineoplastic agents in cancer chemotherapy. We demonstrate for the first time that miR-383 can specifically regulates the expression of Gadd45g by directly targeting to the 3-UTR region of Gadd45g mRNA, a regulatory process conserved in human tumor cells and mouse embryonic stem cells. These two compotents can be potentially used as antineoplastic agents in cancer chemotherapy.
- 21 November 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e110472
Open AccessMicroRNA-383 Regulates the Apoptosis of Tumor Cells through Targeting Gadd45g
MicroRNAs (miRNAs) are a class of small non-coding single-stranded RNA molecules that inhibit gene expression at post-transcriptional level. Gadd45g (growth arrest and DNA-damage-inducible 45 gamma) is a stress-response protein, which has been implicated in several biological processes, including DNA repair, the cell cycle and cell differentiation. In this work, we found that miR-383 is a negative regulator of Gadd45g. Forced expression of miR-383 decreased the expression of Gadd45g through binding to the 3′ untranslated region (3′-UTR), whereas inhibition of miR-383 increased Gadd45g expression. The presence of miR-383 increased the cellular sensitivity to DNA damage in breast cancer cells, which was rescued by ectopic expression of Gadd45g without the 3′-UTR. miR-383 also regulates the expression of Gadd45g in embryonic stem (ES) cells, but not their apoptosis under genotoxic stress. miR-383 was further showed to negatively regulate ES cell differentiation via targeting Gadd45g, which subsequently modulates the pluripotency-associated genes. Taken together, our study demonstrates that miR-383 is a negative regulator of Gadd45g in both tumor cells and ES cells, however, has distinct function in regulating cell apoptosis. miR-383 may be used as antineoplastic agents in cancer chemotherapy. We demonstrate for the first time that miR-383 can specifically regulates the expression of Gadd45g by directly targeting to the 3-UTR region of Gadd45g mRNA, a regulatory process conserved in human tumor cells and mouse embryonic stem cells. These two compotents can be potentially used as antineoplastic agents in cancer chemotherapy.